Clinical trial
A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
- Lead sponsor
- Canadian Cancer Trials Group
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- September 2, 2020
- Completion date
- December 31, 2026
- Enrollment
- 40 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.